ClinVar Miner

Submissions for variant NM_000352.6(ABCC8):c.2857C>T (p.Gln953Ter)

gnomAD frequency: 0.00001  dbSNP: rs541269678
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000169265 SCV000220556 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2014-07-25 criteria provided, single submitter literature only
Genetic Services Laboratory, University of Chicago RCV000169265 SCV000592992 pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2015-12-24 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000780808 SCV000918370 likely pathogenic Familial hyperinsulinism 2018-05-14 criteria provided, single submitter clinical testing Variant summary: ABCC8 c.2857C>T (p.Gln953X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g., p.Arg998X and p.Asp1192fsX16). The variant allele was found at a frequency of 1.6e-05 in 246868 control chromosomes (gnomAD and publications). This frequency is not higher than expected for a pathogenic variant in ABCC8 causing Familial Hyperinsulinism (1.6e-05 vs 3.40e-03), allowing no conclusion about variant significance. The variant, c.2857C>T, has been reported in the literature in multiple individuals affected with Familial Hyperinsulinism (Nestorowicz_1998, Bellanne-Chantelot_2010, Arya_2014, Snider_2013, Valin_2013). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified it as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV001040693 SCV001204282 pathogenic not provided 2024-01-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln953*) in the ABCC8 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ABCC8 are known to be pathogenic (PMID: 20685672, 23345197). This variant is present in population databases (rs541269678, gnomAD 0.004%). This premature translational stop signal has been observed in individuals with congenital hyperinsulinism (PMID: 9618169, 23275527, 23506826, 28442472). This variant is also known as p.Gln954*in the literature. ClinVar contains an entry for this variant (Variation ID: 188905). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Illumina Laboratory Services, Illumina RCV000169265 SCV002038582 pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2021-06-11 criteria provided, single submitter clinical testing The ABCC8 c.2860C>T (p.Gln954Ter) variant is stop-gained variant that is predicted to result in a premature termination or absence of the protein. Across a selection of the available literature, the p.Gln954Ter variant has been reported in at least two individuals with paternally-inherited, monoallelic hyperinsulinemic hypoglycemia and in five individuals with autosomal recessive hyperinsulinemic hypoglycemia (Nestorowicz et al. 1998; Snider et al. 2013; Arya et al. 2014; Li et al. 2017). The p.Gln954Ter variant is reported in at a frequency of 0.00003516 in the European (non-Finnish) population of Genome Aggregation Database version 2.1.1. Based on the collective evidence, the p.Gln954Ter variant is classified as pathogenic for hyperinsulinemic hypoglycemia.
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000169265 SCV002762749 pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2022-08-25 criteria provided, single submitter research ACMG codes:PVS1, PS4M, PM2
Fulgent Genetics, Fulgent Genetics RCV002505223 SCV002809635 pathogenic Diabetes mellitus, transient neonatal, 2; Hyperinsulinemic hypoglycemia, familial, 1; Leucine-induced hypoglycemia; Type 2 diabetes mellitus; Diabetes mellitus, permanent neonatal 3 2022-04-16 criteria provided, single submitter clinical testing
Genetics and Molecular Pathology, SA Pathology RCV000169265 SCV004175338 pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2021-08-18 criteria provided, single submitter clinical testing
Baylor Genetics RCV004567366 SCV005054944 pathogenic Type 2 diabetes mellitus 2023-12-22 criteria provided, single submitter clinical testing
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) RCV001040693 SCV002036399 pathogenic not provided no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV001040693 SCV002037319 likely pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.